Stephen Mandel Ascendis Pharma A/S Transaction History

Lone Pine Capital LLC

  • $12.9 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$127.1 - $169.66 $183 Million - $244 Million
-1,436,981 Closed
0 $0
Q1 2021

May 18, 2021
BUY
$124.92 - $173.33 $67.8 Million - $94 Million
542,448 Added 60.64%
1,436,981 $185 Million
Q4 2020

Feb 16, 2021
BUY
$151.2 - $182.76 $135 Million - $163 Million
894,533 New
894,533 $149 Million

Others Institutions Holding ASND

# of Institutions
244
Shares Held
58.8M
Call Options Held
250K
Put Options Held
377K
View Full List

About Ascendis Pharma A/S

ASND Quotes by TradingView
  • Ticker ASND
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,810,200
  • Market Cap $7.61B
  • Description
  • Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...
More about ASND
Track Stephen Mandel's Portfolio

Track Stephen Mandel Portfolio

Follow Stephen Mandel (Lone Pine Capital LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lone Pine Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lone Pine Capital LLC and Stephen Mandel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email